The ReMEDy2 Phase 2/3 AIS Trial of DM199 surpassed 70% of required interim enrollment, with interim analysis planned in Q4 2026. Management anticipates four separate preeclampsia data readouts and a readout from the fetal growth restriction trial between now and the end of 2027, with these datasets anticipated to inform dose selection for a potential multi-national Phase 3 program in early-onset preeclampsia.
Cyborg Score Rationale
The company has incurred cumulative losses of $182.8 million since inception in 2000. However, DiaMedica maintains $51.3 million in cash, cash equivalents and investments with anticipated runway through 2027, supporting advancement of multiple late-stage clinical programs approaching key inflection points.